HOME >> BIOLOGY >> NEWS
Second generation targeted antibodies - It's all in the binding

The overproduction, or 'overexpression', of the epidermal growth factor receptor (EGFR) is one of the most common aberrations in cancer, and subsequently agents that inhibit EGFR are among the most hotly-pursued potential products in the pharmaceutical industry. Now, just weeks after one of the first anti-EGFR antibodies, ImClone's Erbitux (Cetuximab), was approved for use in Europe and the USA, a 'second generation' anti-EGFR antibody is set to enter early-phase clinical trials in Australia. In two articles recently published in the Journal of Biological Chemistry, research teams from the Melbourne Branch of the international Ludwig Institute for Cancer Research (LICR) have elucidated the unique binding properties of an anti-EGFR antibody, called 806, that is able to discriminate between EGFR molecules on cancer cells and EGFR molecules on normal cells.

"There is already one anti-EGFR antibody on the market, and there are several more in clinical trials," says Dr. Andrew Scott, the Head of the LICR Melbourne Branch's Clinical Program. "Although these anti-EGFR antibodies do show some anti-tumor activity in patients, they are far from ideal because they bind to EGFR on both cancer cells and normal cells. As a result, they target normal tissues as well as the tumor, and side-effects, although mild, are common." Perhaps more importantly, the 'first generation' antibodies are limited in their clinical application and their capacity for improvement. "We need to increase the therapeutic efficacy of the available anti-EGFR antibodies," explains Dr. Scott. "What we would like to do is attach a lethal agent to an anti-EGFR antibody, such as a cytotoxic molecule or a radioisotope, so that the agent is targeted directly to the cancer cell. With the 806 antibody, we should be able to both interfere with EGFR signaling and deliver lethal agents to cancers, without causing severe side-effects through the destruction of normal, healthy cells, particularly in the liver an
'"/>

Contact: Sarah L. White, Ph.D.
swhite@licr.org
212-450-1543
Ludwig Institute for Cancer Research
6-May-2004


Page: 1 2 3

Related biology news :

1. Second call for proposals for the European Young Investigator Award
2. Secondary complications and restoration of function in SCI
3. Second EMBO International Practical Workshop for Science Teachers
4. NTP-CERHR announces the Second Phthalates Expert Panel Meeting to be held December 15-17, 1999
5. In Logged Forests, Hunting of Wildlife Becomes Deadly Second Harvest
6. Iron Supplemented Formula Milk Should Be Free For Inner City Children Into Their Second Year Of Life
7. Oregon Scientists Discover A Second Blood-Brain Barrier; Important Finding For Patients With Brain Cancers And Neurological Disorders
8. When One Gene Has Two Roles, Its Second Function May Be Missed
9. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
10. The Second Visible Human Project Conference
11. Researchers Take A Second Look At Homocysteines Link To Heart Disease

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Second generation targeted antibodies all the binding

(Date:10/30/2014)... bioengineering professor has received a $1.04 million grant ... cartilage tissue and reduce osteoarthritis using a patient,s ... microscaffolding made of biodegradable polymers., Liping Tang, a ... department, said the research is primarily focused on ... battlefield., "We,ve found that if we inject microscaffolding ...
(Date:10/30/2014)... Rochelle, NY, October 30, 2014—Oligonucleotide-based therapeutics present unique ... to cause reproductive and developmental harm. New consensus ... the combined chemical and biological characteristics of these ... Therapeutics , a peer-reviewed journal from Mary ... available free on the Nucleic Acid Therapeutics ...
(Date:10/30/2014)... New York | Heidelberg, 30 October 2014 Biological ... a better understanding of adsorption of solution ions ... biological cells. Now, a new study provides a ... and surrounding solution ions. Joanna Kotyńska and Zbigniew ... the authors of a study describing these findings, ...
Breaking Biology News(10 mins):UTA researcher uses microscaffolding injections to mend cartilage, prevent osteoarthritis 2New guidelines for reproductive & developmental toxicity testing of oligonucleotide drugs 2Ion adsorption matter in biology 2
(Date:10/30/2014)... Dallas, Texas (PRWEB) October 30, 2014 ... China Naltrexone HCL Industryā€¯ is a professional and ... The report provides basic Naltrexone HCL information, including ... as well as industry overview. This research covers ... as well as global industry analysis covering macroeconomic ...
(Date:10/30/2014)... Rancho BioSciences , the scientific ... curated public data source TCGA for several ... data is now available for other oncology groups. ... internal data sources for their Pharma, Government and academic ... data that becomes more easily accessible. Rancho advises ...
(Date:10/30/2014)... 2014 Whitehouse Laboratories has formally announced ... Testing and Package Test Capacity. Responding to growing demands ... dramatic increase in environmental chamber storage space that will ... aging samples to be securely held on site at ... expenditure has already taken place with the recent completion ...
(Date:10/30/2014)... Oct. 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... that management will present a company overview at the Nomura ... ET in Boston, MA. ... the "Investors & Media" section of the Company,s website, ... website within 48 hours and will be archived for a ...
Breaking Biology Technology:Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Rancho BioSciences Manually Curated TCGA Data Sets Available 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
Cached News: